ArticleNPJ breast cancer2021

MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit.

Sanne Løkkegaard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.